Literature DB >> 8854008

Reasons for instability of bacterial vaccines.

M J Corbel1.   

Abstract

Stability problems in relation to bacterial vaccines vary widely between different types of product. Killed whole cell bacterial vaccines including pertussis, cholera and typhoid vaccines generally show a high degree of stability of potency. Reversion to toxicity may occur in incompletely inactivated pertussis vaccines. Live attenuated vaccines such as BCG and Ty21a typhoid vaccines lose potency through loss of viability when exposed to adverse conditions. Both vaccines are susceptible to ultra violet radiation but Ty21a also has low thermal stability. Its fragility is probably a consequence of multiple mutations affecting structural and metabolic factors. Diphtheria and tetanus toxoids generally show high stability of potency. Reversion to toxicity may occur if the toxoiding process is inadequate. Decline in potency may result from exposure to adverse conditions, such as freezing, that affect the interaction with the adjuvant. Similar problems may be encountered with purified subunit vaccines such as acellular pertussis preparations. Some components, in particular pertussis toxin and filamentous haemagglutinin, show inherent low stability and degrade on storage at refrigerator temperatures unless stabilized by a protein cross-linking agent. Bacterial proteases carried over from the cell cultures may also be responsible for degradation of purified components. Purified bacterial polysaccharides usually show high stability if freeze-dried under appropriate conditions. Catalytic degradation may occur however, if the stabilizers are of inadequate purity. Polysaccharide-protein conjugates such as Haemophilus influenzae b (Hib) polyribosylribityl phosphate-protein conjugates show high thermal stability if freeze dried. In the liquid state, such conjugates tend to degrade by hydrolysis of the polysaccharide chains. Combined vaccines may present special stability problems because of the interaction of the various components in the liquid state. It can be difficult to freeze-dry some components of such vaccines, particularly aluminium hydroxide-adsorbed diphtheria-tetanus-pertussis (DTP) components. Slow release vaccines based on polyglycolide-factolide microspheres may show suboptimal stability of encapsulated antigen under both in vitro conditions as a result of gradual acidification through polymer hydrolysis. Vaccines based on the use of live recombinant strains to express heterologous protective antigens may present special stability problems. Apart from the carrier strains, heterologous genes carried on plasmids may be subject to spontaneous deletion under adverse conditions. These issues have received relatively little attention hitherto but are likely to achieve greater prominence as development of such preparations proceeds.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8854008

Source DB:  PubMed          Journal:  Dev Biol Stand        ISSN: 0301-5149


  6 in total

1.  Stability of vaccinia-vectored recombinant oral rabies vaccine under field conditions: a 3-year study.

Authors:  Joseph R Hermann; Alethea M Fry; David Siev; Dennis Slate; Charles Lewis; Donna M Gatewood
Journal:  Can J Vet Res       Date:  2011-10       Impact factor: 1.310

2.  Room temperature stabilization of oral, live attenuated Salmonella enterica serovar Typhi-vectored vaccines.

Authors:  Satoshi Ohtake; Russell Martin; Atul Saxena; Binh Pham; Gary Chiueh; Manuel Osorio; Dennis Kopecko; Deqi Xu; David Lechuga-Ballesteros; Vu Truong-Le
Journal:  Vaccine       Date:  2011-02-05       Impact factor: 3.641

3.  Humanized nonobese diabetic-scid IL2rgammanull mice are susceptible to lethal Salmonella Typhi infection.

Authors:  Stephen J Libby; Michael A Brehm; Dale L Greiner; Leonard D Shultz; Michael McClelland; Kelly D Smith; Brad T Cookson; Joyce E Karlinsey; Traci L Kinkel; Steffen Porwollik; Rocio Canals; Lisa A Cummings; Ferric C Fang
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-16       Impact factor: 11.205

4.  Synthetic Toll-like receptor 4 agonist enhances vaccine efficacy in an experimental model of toxic shock syndrome.

Authors:  Garry L Morefield; Lynn D Hawkins; Sally T Ishizaka; Teri L Kissner; Robert G Ulrich
Journal:  Clin Vaccine Immunol       Date:  2007-08-22

5.  Protection against avian necrotic enteritis after immunisation with NetB genetic or formaldehyde toxoids.

Authors:  Sérgio P Fernandes da Costa; Dorien Mot; Monika Bokori-Brown; Christos G Savva; Ajit K Basak; Filip Van Immerseel; Richard W Titball
Journal:  Vaccine       Date:  2013-05-29       Impact factor: 3.641

6.  CpG ODN1826 as a Promising Mucin1-Maltose-Binding Protein Vaccine Adjuvant Induced DC Maturation and Enhanced Antitumor Immunity.

Authors:  Jing Jie; Yixin Zhang; Hongyue Zhou; Xiaoyu Zhai; Nannan Zhang; Hongyan Yuan; Weihua Ni; Guixiang Tai
Journal:  Int J Mol Sci       Date:  2018-03-20       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.